Atrial Fibrillation Management

Initial Treatment Strategy

• The American College of Cardiology recommends rate control with chronic anticoagulation as the initial treatment strategy for most patients with newly diagnosed atrial fibrillation, rather than cardioversion to sinus rhythm, as it focuses on controlling ventricular response and providing appropriate anticoagulation 1
• The AFFIRM study showed no difference in survival or quality of life between rate control and rhythm control strategies, supporting the use of rate control as the preferred first-line strategy 1

Cardioversion Indications

• The European Heart Society recommends considering cardioversion in patients with hemodynamic instability, such as those with acute MI, symptomatic hypotension, angina, or heart failure not responding to pharmacological measures 2
• Cardioversion should be considered in symptomatic patients when symptoms of AF are unacceptable despite adequate rate control, including those with significant exercise intolerance, and patient preference after discussing risks and benefits 2, 3
• The European Heart Society suggests that at least one attempt at cardioversion may be reasonable for first episodes, especially in younger patients with healthy hearts 3

Cardioversion Contraindications

• The European Heart Society recommends avoiding cardioversion in patients with spontaneous alternation between AF and sinus rhythm, and after multiple failed cardioversion attempts despite prophylactic antiarrhythmic therapy 2

Cardioversion Methods

• Direct-current (electrical) cardioversion has a higher immediate success rate (>90% with biphasic defibrillators) and requires sedation/anesthesia, with a Grade 1C+ recommendation 4
• Pharmacological cardioversion is effective with agents including ibutilide, flecainide, dofetilide, propafenone, and amiodarone, but carries a higher risk of ventricular arrhythmias (up to 9% with ibutilide), and has a Grade 2A recommendation 4

Anticoagulation

• The European Heart Society recommends anticoagulation for at least 3 weeks before and 4 weeks after cardioversion for AF ≥48 hours or unknown duration 3
• The American College of Cardiology suggests that patients at high risk for stroke benefit from anticoagulation even after sinus rhythm restoration, based on the AFFIRM study results 1
• All patients with atrial fibrillation should receive chronic anticoagulation with adjusted-dose warfarin unless they are at low risk of stroke or have specific contraindications, such as thrombocytopenia or recent trauma, as recommended by the American College of Cardiology 4

Maintenance of Sinus Rhythm

• Maintenance of sinus rhythm after cardioversion is moderate to low for both electrical and pharmacological methods, with recurrence common, especially in patients with enlarged left atria 4
• Rhythm control is indicated for patients with significant symptoms despite adequate rate control, exercise intolerance, patient preference, and younger patients, according to the Annals of Internal Medicine 4
• First-line agents, such as beta-blockers or non-dihydropyridine calcium channel blockers, are recommended for their demonstrated efficacy in controlling heart rate both during exercise and at rest, as stated by the American College of Cardiology 4
• Digoxin should only be used as a second-line agent, as it is only effective for rate control at rest, and should be avoided as monotherapy in physically active patients, according to the American College of Cardiology 4
• Rhythm control may be considered based on special considerations, such as significant symptoms despite adequate rate control, patient preference, or exercise intolerance, as recommended by the American College of Cardiology 4
• Direct-current cardioversion (Grade 1C+) and pharmacological conversion (Grade 2A) are options for rhythm control, according to the American College of Cardiology 4
• Most patients converted to sinus rhythm should not be placed on rhythm maintenance therapy, as the risks outweigh the benefits, according to the American College of Cardiology 4
• Rhythm control has not been shown superior to rate control in reducing morbidity and mortality, and may be inferior in some patient subgroups, according to the American College of Cardiology 4